search
Back to results

The Effects of Sesame Extract on the Quality of Life and Antioxidative Status in Sleeping Disorder Patients

Primary Purpose

Sleeping Disorders

Status
Recruiting
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
sesame extract
placebo
Sponsored by
Taipei Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Sleeping Disorders focused on measuring Sleeping Disorders, sesamin, antioxidant

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Aged 20-80 years old Sleeping disorder patients with not or with low arousal threshold obstructive sleep apnea that were diagnosed by the doctor after PSG examination. Exclusion Criteria: Chronic diseases: liver, renal, gastrointestinal, cardiovascular diseases Cancer Pregnant Be allergy to the intervention materials or having supplements /drugs which might affect the study outcome.

Sites / Locations

  • Taipei Medical University-Shuang Ho Hospital,Ministry of Health and WelfareRecruiting
  • Taipei Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

sesame extract

placebo

Arm Description

Dietary supplement: sesame extract (contains sesamin 37-56mg per capsule) This group will be given supplements for 8 weeks.

Placebo treatment ( identical capsules containing Lactose, Silica, Magnesium Stearate, Gelatin)

Outcomes

Primary Outcome Measures

Change from Baseline The Pittsburgh Sleep Quality Index (PSQI) at two months
PSQI is used to evaluate sleeping quality. A self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
Change from Baseline Epworth Sleepiness Scale (ESS) at two months
ESS i a self-administered questionnaire, and is used to assess the 'daytime sleepiness' of the patients.
Change from Baseline Beck Depression Inventory-II (BDI-11) score at two months
BDI-11 is a self-report questionnaire rating measurements characteristic attitudes and symptoms of depression.
Change from Baseline Beck Anxiety Inventory (BAI) score at two months
BAI is a self-report questionnaire that is used for measuring the severity of anxiety.
Change from Baseline Short form-12 items health survey (SF-12) at two months
SF-12 is a general health questionnaire, which evaluated quality of life.

Secondary Outcome Measures

Anthropometric assessmrnt
BMI (kg/m^2), body composition and blood pressure (mmHg)
Liver function
Serum AST and ALT (U/L)
Kidney function
Serum BUN (mg/dL),Creatinine (mg/dL), eGFR (mL/min) and urine acid (mg/dL)
Lipid profile
Serum HDL-C, LDL-C, triglyceride and total cholesterol (mg/dL)
Hematology
WBC (10^3/uL), RBC (10^6/uL), hemoglobin (g/dL), hematocrit (%), MCV(fL), MCH (pg), MCHC (g/dL), platelet (10^3/uL), neutrophils (%), lymphocytes (%), monocytes (%), eosinophils (%) and basophils(%).
Antioxidative status
Concentration of thiobarbituric acid-reactive substance, glutathione/oxidized glutathione ratio
Sesamin and it's metabolite
Concentration of serum sesamin and it's metabolite

Full Information

First Posted
October 2, 2022
Last Updated
January 16, 2023
Sponsor
Taipei Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT05678439
Brief Title
The Effects of Sesame Extract on the Quality of Life and Antioxidative Status in Sleeping Disorder Patients
Official Title
The Effects of Sesame Extract on the Quality of Life and Antioxidative Status in Sleeping Disorder Patients
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 18, 2022 (Actual)
Primary Completion Date
July 20, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Taipei Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Sesame recognized as a common healthy food. Sesamin is extracted from sesame and has high antioxidant capacity which is commonly added in functional foods. Present studies had found sesamin supplementation could improve self-reported fatigue but more evidence should be clarify. The purpose of this study is to evaluate the effects of sesame extract on the quality of life and antioxidative status on sleeping disorder patients with not or with low arousal threshold obstructive sleep apnea and assess the potential product development.
Detailed Description
30-50 subjects aged from 20 to 80 years old without sleep apnea or with low arousal threshold obstructive sleep apnea will be enrolled in this randomized, double-blind, cross-over, and placebo-controlled 8-week period experiment. At the treatment period (0th to 8th week of the experiment), subjects will receive 2 placebo or capsules of sesame complex (37-56mg sesamin per capsule). The 9th to 11th week will be the washout period. The control and sesamin group will be cross-over at 11th week to 12th week of the experiment. Sleep quality, life quality examination and anti-oxidative functions will be carried out in this study. The basic anthropometric examination will be carried out at the beginning, 4th, 8th, 11th, 15th, and 19th week of the study. Routine laboratory parameters including liver function, kidney function, blood sugar, lipid profile, and anti-oxidative status will be investigated at the beginning, 8th, 11th and 19th week of the study. The questionnaire evaluation including the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, Beck Depression Inventory-II, Beck Anxiety Inventory, and Short form-12 items health survey will be investigated at the beginning, 8th, 11th, and 19th week of the study. We expect that sesame complex including 37-56mg sesamin may improve oxidative status which in turn ameliorates the sleep quality, life quality, and anti-oxidative functions in patients with sleep disorder.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleeping Disorders
Keywords
Sleeping Disorders, sesamin, antioxidant

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
sesame extract
Arm Type
Experimental
Arm Description
Dietary supplement: sesame extract (contains sesamin 37-56mg per capsule) This group will be given supplements for 8 weeks.
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Placebo treatment ( identical capsules containing Lactose, Silica, Magnesium Stearate, Gelatin)
Intervention Type
Dietary Supplement
Intervention Name(s)
sesame extract
Intervention Description
At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
Primary Outcome Measure Information:
Title
Change from Baseline The Pittsburgh Sleep Quality Index (PSQI) at two months
Description
PSQI is used to evaluate sleeping quality. A self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Title
Change from Baseline Epworth Sleepiness Scale (ESS) at two months
Description
ESS i a self-administered questionnaire, and is used to assess the 'daytime sleepiness' of the patients.
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Title
Change from Baseline Beck Depression Inventory-II (BDI-11) score at two months
Description
BDI-11 is a self-report questionnaire rating measurements characteristic attitudes and symptoms of depression.
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Title
Change from Baseline Beck Anxiety Inventory (BAI) score at two months
Description
BAI is a self-report questionnaire that is used for measuring the severity of anxiety.
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Title
Change from Baseline Short form-12 items health survey (SF-12) at two months
Description
SF-12 is a general health questionnaire, which evaluated quality of life.
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Secondary Outcome Measure Information:
Title
Anthropometric assessmrnt
Description
BMI (kg/m^2), body composition and blood pressure (mmHg)
Time Frame
At the start of the experiment and at the 4th, 8th, 11th, 15th and 19th week
Title
Liver function
Description
Serum AST and ALT (U/L)
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Title
Kidney function
Description
Serum BUN (mg/dL),Creatinine (mg/dL), eGFR (mL/min) and urine acid (mg/dL)
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Title
Lipid profile
Description
Serum HDL-C, LDL-C, triglyceride and total cholesterol (mg/dL)
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Title
Hematology
Description
WBC (10^3/uL), RBC (10^6/uL), hemoglobin (g/dL), hematocrit (%), MCV(fL), MCH (pg), MCHC (g/dL), platelet (10^3/uL), neutrophils (%), lymphocytes (%), monocytes (%), eosinophils (%) and basophils(%).
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Title
Antioxidative status
Description
Concentration of thiobarbituric acid-reactive substance, glutathione/oxidized glutathione ratio
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week
Title
Sesamin and it's metabolite
Description
Concentration of serum sesamin and it's metabolite
Time Frame
At the start of the experiment and at the 8th, 11th and 19th week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 20-80 years old Sleeping disorder patients with not or with low arousal threshold obstructive sleep apnea that were diagnosed by the doctor after PSG examination. Exclusion Criteria: Chronic diseases: liver, renal, gastrointestinal, cardiovascular diseases Cancer Pregnant Be allergy to the intervention materials or having supplements /drugs which might affect the study outcome.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Suh-Ching Yang
Phone
+886-2-2736-1661
Ext
6553
Email
sokei@tmu.edu.tw
Facility Information:
Facility Name
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare
City
New Taipei City
ZIP/Postal Code
235
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wen-Te Liu
Email
lion5835@gmail.com
Facility Name
Taipei Medical University
City
Taipei
ZIP/Postal Code
110
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Suh-Ching Yang
Phone
+886-2-2736-1661
Ext
6553
Email
sokei@tmu.edu.tw

12. IPD Sharing Statement

Learn more about this trial

The Effects of Sesame Extract on the Quality of Life and Antioxidative Status in Sleeping Disorder Patients

We'll reach out to this number within 24 hrs